Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims

Zacks05-03

The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432186167?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","is_english":true,"pubTime":"2024-05-03 23:29","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2432186167","market":"us","top_or_hot":-1,"title":"Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims","media":"Zacks","content":"<div>\n<p>The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-lly-nvo-152900508.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 23:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pharma-stock-roundup-lly-nvo-152900508.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-lly-nvo-152900508.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-lly-nvo-152900508.html","article_id":"2432186167","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432186167","pubTimestamp":1714750140,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely resolve its talc-related lawsuits.Earnings Update: Pfizer’s first-quarter results were strong as it beat estimates for earnings as well as sales. While sales of COVID products declined due to lower demand, some key non-COVID products like Prevnar, Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products from Seagen boosted the top line in the first quarter. Sales of all key products like Prevnar, Vyndaqel and Eliquis beat estimates. Seagen drugs contributed $742 million to the top line in the first quarter. Revenues from Pfizer’s non-COVID products rose 11% operationally in the first quarter.Backed by strong sales performance of Ozempic and Wegovy, Novo Nordisk raised its sales growth expectation for 2024 from a range of 18","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","JNJ":"强生","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LLY":"礼来","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4534":"瑞士信贷持仓","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","BK4139":"生物科技","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4007":"制药","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","PFE":"辉瑞","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4568":"美国抗疫概念","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","FIX":"美国舒适系统","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","ABBV":"艾伯维公司","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC"},"translate_title":"制药股票综述：LLY，NVO，PFE Q1结果，JNJ解决滑石索赔的新计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"PFE":1,"FIX":1,"NVO":1,"JNJ":1,"LLY":1},"content_text":"The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely resolve its talc-related lawsuits.\nRecap of the Week’s Most Important Stories\nEarnings Update: Pfizer’s first-quarter results were strong as it beat estimates for earnings as well as sales. While sales of COVID products declined due to lower demand, some key non-COVID products like Prevnar, Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products from Seagen boosted the top line in the first quarter. Sales of all key products like Prevnar, Vyndaqel and Eliquis beat estimates. Seagen drugs contributed $742 million to the top line in the first quarter. Revenues from Pfizer’s non-COVID products rose 11% operationally in the first quarter.\nThe company raised its 2024 earnings guidance while retaining revenue expectations. Adjusted earnings are expected in the range of $2.15 to $2.35 versus the prior expectation of $2.05 to $2.25 per share.The revenue guidance was maintained in the range of $58.5 to $61.5 billion in 2024, almost flat from the 2023 levels.\nLilly’s first-quarter results were soft as it beat estimates for earnings but missed the same for sales. Strong demand for Mounjaro, Zepbound, Verzenio and Jardiance pulled the top line in the quarter. However, continued supply constraints for incretin-based products like Trulicity, Mounjaro and Zepbound hurt sales. Demand for incretin-based products exceeded supply.\nMounjaro recorded sales of $1.81 billion during the quarter, while Zepbound’s sales were $517.4 million. Lilly is investing in new advanced manufacturing plants and lines in the United States and Europe to increase supply. Lilly expects the production of incretin-based products to increase from the second half of 2024. “Greater visibility” on its production expansion plans and strong demand for Mounjaro and Zepbound pushed Lilly to raise its sales and earnings guidance ranges for 2024. Lilly expects revenues in the range of $42.4 billion to $43.6 billion compared with the prior expectation of $40.4 to $41.6 billion. The earnings per share guidance was raised from the range of $12.20 to $12.70 to $13.50 to $14.00 per share.\nNovo Nordisk beat estimates for both earnings and sales. Revenues rose 24% at a constant exchange rate (CER), driven by strong sales of its diabetes and obesity care products, mainly GLP-1 products. Its GLP-1 diabetes sales increased 32% at CER. Total Diabetes care rose 24% and Obesity care sales increased 42% at CER. Sales of the diabetes drug Ozempic rose 43%, while Wegovy rose 107% at CER. Rare disease segment sales were down 3%.\nBacked by strong sales performance of Ozempic and Wegovy, Novo Nordisk raised its sales growth expectation for 2024 from a range of 18-26% at CER to 19-27%, while the operating profit growth range was raised from 21-29% to 22-30%at CER.\nAbbVie beat estimates for both earnings and sales in the first quarter. While sales rose 0.7% year over year, earnings declined 6.1%. Sales of key immunology medicines Skyrizi and Rinvoq rose 47.6% and 59.3% on a reported basis, respectively, driven by successful label expansions to new indications. Humira sales declined 35.9% due to generic erosion. The company also raised its EPS guidance for 2024. AbbVie expects adjusted EPS in the range of $11.13-$11.33, up from the previously provided EPS guidance of $10.97-$11.17.\nFDA Approves Pfizer’s Hemophilia Gene Therapy: The FDA granted approval to Pfizer’s gene therapy fidanacogene elaparvovec for the treatment of adults with hemophilia B, a rare genetic bleeding disorder. The therapy will be marketed by the name of Beqvez. Beqvez is a one-time treatment which will allow hemophilia B patients to produce factor IX (FIX), a blood clotting factor, themselves compared to the current standard of care, which require regular FIX infusions, thereby reducing the treatment burden for these patients. The approval is based on positive data from the phase III study called BENEGENE-2. A regulatory application is also under review in Europe. Beqvez was recently approved in Canada.\nJ&J’s New Plan to Resolve Talc Lawsuits: J&J announced that its subsidiary, LTL Management, which was established to manage claims in the cosmetic talc litigation, has proposed a “Plan of Reorganization” to resolve all present and future pending ovarian cancer talc lawsuits\nJ&J faces more than 50,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer.\nLTL Management twice filed for voluntary bankruptcy to equitably resolve all present and future talc-related claims. However, both the bankruptcy filings were rejected by courts stating that J&J was not in enough financial stress to qualify for bankruptcy.\nPer the new plan, to completely resolve its cosmetic talc litigation, J&J has offered to pay $6.48 billion to claimants over a period of 25 years. If 75% of claimants vote in favor of the plan, J&J will file a third bankruptcy filing. The company claims that if the plan is approved by claimants through a majority vote, it would resolve 99.75% of all pending talc lawsuits against J&J.\nJ&J filed regulatory applications to the European Medicines Agency (EMA) seeking approval for its immunology medicine, Tremfya, for two new indications — moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn’s disease.\nTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. The applications for the UC indication were based on data from the phase III QUASAR study, while that for Crohn’s disease was based on the phase III GALAXI. J&J has also filed an application seeking expanded use of Tremfya for the UC indication to the FDA.\nThe NYSE ARCA Pharmaceutical Index rose 1.2% in the last five trading sessions.\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\nHere’s how the eight major stocks performed in the last five trading sessions.\n\nImage Source: Zacks Investment Research\nIn the last five trading sessions, Pfizer rose the most (9.6%), while AbbVie declined the most (3.9%).\nIn the past six months, Lilly has risen the highest (27.0%), while Pfizer has declined the most (11.2%).\n(See the last pharma stock roundup here: MRK, SNY, AZN, NVS’ Q1 Results, Pipeline & Regulatory Updates)\nWhat's Next in the Pharma World?\nWatch this space for regular pipeline and regulatory updates next week.\nLilly, Pfizer, Novo Nordisk, AbbVie and J&J have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432186167"}